Table 4.
Clinical outcomes by ceftaroline fosamil line of therapy
| Outcome measure | All patients (n = 185) | Patients with severe CAP (n = 128) | ||
|---|---|---|---|---|
| First-line ceftaroline fosamil (n = 50) | Later-line ceftaroline fosamil (n = 135) | First-line ceftaroline fosamil (n = 35) | Later-line ceftaroline fosamil (n = 93) | |
| Treatment response, n (%) | ||||
| Clinical responsea | 44 (88.0) | 107 (79.3) | 29 (82.9) | 75 (80.7) |
| Clinical failure | 6 (12.0) | 28 (20.7) | 6 (17.1) | 18 (19.4) |
| Time to clinical response, days, mean (SD) | 4.9 (3.3) | 5.1 (3.6) | 5.5 (3.4) | 5.8 (3.8) |
| Early clinical response, n (%) | ||||
| >4 days | 18/44 (40.9) | 44/107 (41.1) | 16/29 (55.2) | 38/75 (50.7) |
| ≤4 days | 25/44 (56.8) | 54/107 (50.5) | 13/29 (44.8) | 33/75 (44.0) |
| Unknown | 1/44 (2.3) | 9/107 (8.4) | 0 | 4/75 (5.3) |
| Clinical cure achieved, n (%) | ||||
| Yes | 33 (66.0) | 82 (60.7) | 22 (62.9) | 56 (60.2) |
| No | 10 (20.0) | 25 (18.5) | 6 (17.1) | 19 (20.4) |
| Unknown | 7 (14.0) | 28 (20.7) | 7 (20.0) | 18 (19.4) |
| Time to clinical cure, days, mean (SD) | 6.7 (4.0) | 8.3 (4.4) | 7.1 (4.5) | 8.5 (4.0) |
| Time to clinical stability, days, mean (SD) | 3.6 (2.4) | 3.9 (3.1) | 4.1 (2.4) | 4.6 (3.2) |
| Time to clinical improvement, days, mean (SD) | 4.9 (3.4) | 4.4 (3.3) | 5.4 (3.5) | 4.9 (3.6) |
aDefined as demonstrating clinical stability (defined according to the IDSA guidelines20 as temperature of ≤37.8°C, heart rate of ≤100 beats/min, respiratory rate of ≤24 breaths/min, systolic blood pressure of ≥90 mmHg, oxygen saturation of ≥90%, and confusion/disorientation recorded as absent) and clinical improvement [defined as improvement of at least one of four symptoms present at baseline (i.e. cough, dyspnoea, pleuritic chest pain or sputum production) with worsening of none].